Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0CY1B
|
|||
| Former ID |
DCL000010
|
|||
| Drug Name |
CYC116
|
|||
| Synonyms |
693228-63-6; CYC-116; CYC116; CHEMBL482967; Kinome_636; 4-methyl-5-(2-(4-morpholinophenylamino)pyrimidin-4-yl)thiazol-2-amine; 4-Methyl-5-(2-((4-morpholinophenyl)amino)-pyrimidin-4-yl)thiazol-2-amine; 4-methyl-5-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine; 4-methyl-5-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)thiazol-2-amine; 2uue; CYC 116; GPSZYOIFQZPWEJ-UHFFFAOYSA-N; 2c5t; AC1O4WKE; MLS006011244; SCHEMBL2074998; SYN1034; EX-A753; CYC-116/CYC116; MolPort-009-679-476; HMS3244O12; HMS3244P11; BCPP000273
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Cyclacel Limited
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H20N6OS
|
|||
| Canonical SMILES |
CC1=C(SC(=N1)N)C2=NC(=NC=C2)NC3=CC=C(C=C3)N4CCOCC4
|
|||
| InChI |
1S/C18H20N6OS/c1-12-16(26-17(19)21-12)15-6-7-20-18(23-15)22-13-2-4-14(5-3-13)24-8-10-25-11-9-24/h2-7H,8-11H2,1H3,(H2,19,21)(H,20,22,23)
|
|||
| InChIKey |
GPSZYOIFQZPWEJ-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
11618518, 16832086, 24424536, 43014321, 46393965, 50521546, 99436925, 103652037, 103904403, 104120139, 114518369, 124757050, 125163854, 125329932, 125650062, 131480715, 134339467, 135685404, 135685405, 135685424, 136367344, 136367981, 136920315, 137276048, 141791974, 144115863, 152037316, 152258254, 152344039, 160647090, 162011811, 162037480, 162202552, 164194001, 170481285, 174561022, 180190851, 185965274, 188899569, 223653845, 223705256, 223964817, 228221334, 246870915, 249814521, 251963051, 252215210, 252451655, 252543304
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00560716) A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Cyclacel. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.